Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Amarin Corporation PLC (AMRN : NSDQ)

• Company Description    Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid for treating cardiovascular diseases. The company's sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride levels. The FDA approved Vascepa to reduce cardiovascular risk in patients with persistent elevated triglycerides on statin therapy for LDL-C. The drug received approval for both indications in Europe under the tradename of Vazkepa. It has initiated various promotional activities and direct-to-consumer programs as well as expanded its salesforce to support promotion of Vascepa's expanded label. A generic version of Vascepa has been launched for elevated TG levels. Number of Employees: 275

• Price / Volume Information    Yesterday's Closing Price: $13.95 Daily Weekly Monthly 20 Day Moving Average: 91,472 shares Shares Outstanding: 20.79 (millions) Market Capitalization: $290.16 (millions) Beta: 0.72 52 Week High: $20.90 52 Week Low: $7.08 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -14.33% -14.28% 12 Week -27.62% -28.59% Year To Date 43.87% 23.61%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE CENTRAL PLAZA 8TH FLOOR DAME STREET - DUBLIN,L2 D02 K7K5 IRL ph: 353-1669-9020 fax: - investor.relations@amarincorp.com http://www.amarincorp.com

• General Corporate Information    Officers Aaron Berg - Director; President and Chief Executive Officer Peter Fishman - Senior Vice President and Chief Financial Officer Patrice Bonfiglio - Director Paul Cohen - Director Mark DiPaolo - Director Peer Information Amarin Corporation PLC (CORR.) Amarin Corporation PLC (RSPI) Amarin Corporation PLC (CGXP) Amarin Corporation PLC (BGEN) Amarin Corporation PLC (GTBP) Amarin Corporation PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 023111404 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/11/26 Share - Related Items Shares Outstanding: 20.79 Most Recent Split Date: 4.00 (0.05:1) Beta: 0.72 Market Capitalization: $290.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.06 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.63 Price/Cash Flow: - Price / Sales: 1.28 EPS Growth vs. Year Ago Period: 100.00% vs. Previous Quarter: 100.00% Sales Growth vs. Year Ago Period: 17.43% vs. Previous Quarter: -31.72% ROE 12/31/25 - - 09/30/25 - -16.31 06/30/25 - -21.18 ROA 12/31/25 - - 09/30/25 - -11.50 06/30/25 - -15.00 Current Ratio 12/31/25 - - 09/30/25 - 3.45 06/30/25 - 3.26 Quick Ratio 12/31/25 - - 09/30/25 - 2.43 06/30/25 - 2.34 Operating Margin 12/31/25 - - 09/30/25 - -33.87 06/30/25 - -47.22 Net Margin 12/31/25 - - 09/30/25 - -38.01 06/30/25 - -47.22 Pre-Tax Margin 12/31/25 - - 09/30/25 - -37.53 06/30/25 - -44.91 Book Value 12/31/25 - - 09/30/25 - 22.07 06/30/25 - 22.48 Inventory Turnover 12/31/25 - - 09/30/25 - 0.81 06/30/25 - 0.76 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©